Oral GLP‑1 Approved

Weight-loss drugs that mimic a gut hormone have mostly meant weekly shots. In December 2025, the Food and Drug Administration approved Wegovy tablets, making semaglutide the first oral glucagon-like peptide-1 drug cleared in the U.S. for chronic weight management. (fda.gov) The tablet is approved for adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The label also includes adults with established cardiovascular disease and obesity or overweight for reducing the risk of heart attack, stroke, or cardiovascular death. (fda.gov) In the phase 3 OASIS 4 trial, adults taking oral semaglutide 25 milligrams lost an average of 13.6% of body weight at 64 weeks, versus 2.2% with placebo, according to AJMC’s report on the approval. The study enrolled 307 adults with obesity or overweight. (ajmc.com) Applied Clinical Trials reported a higher figure from OASIS 4, saying oral semaglutide produced 16.6% mean weight loss and improved blood sugar and cardiovascular risk factors versus placebo. The difference appears to reflect different trial analyses rather than a different study. (appliedclinicaltrialsonline.com) Semaglutide works by acting like glucagon-like peptide-1, a hormone released after eating that helps people feel fuller and slows stomach emptying. That mechanism turned injectable Wegovy and diabetes drug Ozempic into blockbuster treatments, but injections, supply constraints, and insurance limits have narrowed access. (fda.gov) (ajmc.com) A pill changes the format, not the basic tradeoffs. The FDA label carries the same boxed warning about thyroid C-cell tumors seen across semaglutide products and says the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) Novo Nordisk said before launch that it planned to bring the Wegovy pill to the U.S. in early January 2026. By April 2026, the company’s U.S. news archive had shifted to newer Wegovy pricing and access announcements, showing how quickly the oral obesity market was moving. (appliedclinicaltrialsonline.com) (novonordisk-us.com) The market did not stay exclusive for long. On April 1, 2026, the FDA also approved Eli Lilly’s oral obesity drug orforglipron, giving doctors and patients a second pill option and intensifying competition over dosing convenience, supply, and price. (ajmc.com) The opening move was a pill instead of a shot. Four months later, it already looks like the start of a crowded oral obesity-drug market, not the end of one. (ajmc.com 1) (ajmc.com 2)